1-3 of 3
Dominick Bossé
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma

Rana R. McKay, Dominick Bossé, Wanling Xie, Stephanie A.M. Wankowicz, Abdallah Flaifel, Raphael Brandao, Aly-Khan A. Lalani, Dylan J. Martini, Xiao X. Wei, David A. Braun, Eliezer Van Allen, Daniel Castellano, Guillermo De Velasco, J. Connor Wells, Daniel Y. Heng, Andre P. Fay, Fabio A. Schutz, JoAnn Hsu, Sumanta K. Pal, Jae Lyun Lee, James J. Hsieh, Lauren C. Harshman, Sabina Signoretti, Robert J. Motzer, Darren Feldman, Toni K. Choueiri
Journal: Cancer Immunology Research
Cancer Immunol Res (2018) 6 (7): 758–765.
https://doi.org/10.1158/2326-6066.CIR-17-0475
Published: 01 July 2018
View article titled, The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
Open the PDF for The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events

Dylan J. Martini, Lana Hamieh, Rana R. McKay, Lauren C. Harshman, Raphael Brandao, Craig K. Norton, John A. Steinharter, Katherine M. Krajewski, Xin Gao, Fabio A. Schutz, Bradley McGregor, Dominick Bossé, Aly-Khan A. Lalani, Guillermo De Velasco, M. Dror Michaelson, David F. McDermott, Toni K. Choueiri
Journal: Cancer Immunology Research
Cancer Immunol Res (2018) 6 (4): 402–408.
https://doi.org/10.1158/2326-6066.CIR-17-0220
Published: 01 April 2018
View article titled, Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
Open the PDF for Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events in another window
Journal Articles

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

Guillermo De Velasco, Youjin Je, Dominick Bossé, Mark M. Awad, Patrick A. Ott, Raphael B. Moreira, Fabio Schutz, Joaquim Bellmunt, Guru P. Sonpavde, F. Stephen Hodi, Toni K. Choueiri
Journal: Cancer Immunology Research
Cancer Immunol Res (2017) 5 (4): 312–318.
https://doi.org/10.1158/2326-6066.CIR-16-0237
Published: 02 April 2017
View article titled, Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
Open the PDF for Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients in another window
Includes: Supplementary data